Adjuvant T-DM1 was associated with favorable survival outcomes in individuals with early-stage HER2-positive breast cancer who had residual disease following neoadjuvant treatment, across the different neoadjuvant regimens represented in our cohort. This evidence concerns the gene ERBB2 and breast cancer.